Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer

Personalised oncogenomics analysis revealed potential oncogene addiction of the AP-1 transcriptional complex in a chemo-refractory and MMR-deficient tumor from a patient with metastatic colon cancer. Based on this, treatment with the angiotensin receptor agonist irbesartan was initiated to target the renin–angiotensin system upstream of the AP-1 complex, leading to a profound and durable response.

[1]  Ting Yang,et al.  Association between Metformin Therapy and Breast Cancer Incidence and Mortality: Evidence from a Meta-Analysis , 2015, Journal of breast cancer.

[2]  R. Winfield,et al.  Angiotensin Inhibition Is Associated with Preservation of T-Cell and Monocyte Function and Decreases Multiple Organ Failure in Obese Trauma Patients. , 2015, Journal of the American College of Surgeons.

[3]  R. Morita,et al.  Smad2 and Smad3 Inversely Regulate TGF-β Autoinduction in Clostridium butyricum-Activated Dendritic Cells. , 2015, Immunity.

[4]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Gröne,et al.  Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells , 2014, Oncology letters.

[6]  H. Dietz,et al.  The genetic basis of aortic aneurysm. , 2014, Cold Spring Harbor perspectives in medicine.

[7]  Peter J. Park,et al.  The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes , 2013, Cell.

[8]  Jose M Garcia,et al.  Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer. , 2013, Translational oncology.

[9]  H. Kuniyasu.  Multiple roles of angiotensin in colorectal cancer. , 2012, World journal of clinical oncology.

[10]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[11]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[12]  R. Akhurst,et al.  Complexities of TGF-β Targeted Cancer Therapy , 2012, International journal of biological sciences.

[13]  D. Sgroi,et al.  A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas , 2011, Clinical Cancer Research.

[14]  H. Dietz,et al.  Circulating Transforming Growth Factor-&bgr; in Marfan Syndrome , 2009, Circulation.

[15]  Y. Wan,et al.  Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy , 2007, Clinical Cancer Research.

[16]  H. McLeod,et al.  Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. , 2005, American journal of clinical pathology.

[17]  D. Chang,et al.  Irbesartan inhibits human T‐lymphocyte activation through downregulation of activator protein‐1 , 2004, British journal of pharmacology.

[18]  Shao-Liang Chen,et al.  Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats. , 2004, World journal of gastroenterology.

[19]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[20]  H. Wang,et al.  Expression of Jun family members in human colorectal adenocarcinoma. , 2000, Carcinogenesis.

[21]  W. Jiménez,et al.  Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. , 1999, Kidney international.

[22]  Chul-hak Yang,et al.  Inhibition of fos-jun-DNA complex formation by dihydroguaiaretic acid and in vitro cytotoxic effects on cancer cells. , 1998, Cancer letters.

[23]  D. Cohen,et al.  Transcriptional regulation in the immune system: all roads lead to AP‐1 , 1998, Journal of leukocyte biology.

[24]  J. H. Carter,et al.  Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[25]  A. Bosserhoff,et al.  AP-1/c-Jun transcription factors: regulation and function in malignant melanoma. , 2014, European journal of cell biology.

[26]  H. Iwao,et al.  AP-1 and colorectal cancer , 2006, InflammoPharmacology.

[27]  H. Mizuguchi,et al.  Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer , 2004, Gene Therapy.